why choose us

First received: August 31, 2023

Clinical Trial: MT2022-01: MSCs for ALD

Study Status: Completed

Recruit Status: RECRUITING

Condition: Cerebral Adrenoleukodystrophy

Study Type: INTERVENTIONAL


Official Title: Intravenous Administration of Mesenchymal Stem Cells (IV-MSC) for the Treatment of Cerebral Adrenoleukodystrophy (cALD)

Brief Summary: This is a single-institution study to evaluate the use of intravenously administered allogeneic, 3rd party mesenchymal stem cells (IV-MSC) in patients with active, cerebral adrenoleukodystrophy (CALD), as a bridge to hematopoietic stem cell transplant or gene therapy, or in patients who are too advanced for gene therapy or HSCT.The intervention will occur in the time between diagnosis of active CALD and transplant which is currently 8-12 weeks.

Read more